Acino Estonia OÜ
Active Registry code 14072902
OÜ Põlva linn Registered 30 Jun 2016
Acino Estonia OÜ is a OÜ based in Põlva linn, registry code 14072902, status: active. Main activity: Manufacture of basic pharmaceutical products. According to EMTA, turnover for Q3 2026 was €7 770 168 with 112 employees.
Turnover
7 770 168 €
↓ 11.1% vs Q2 2026
State taxes
517 739 €
↓ 33.7% vs Q2 2026
Labour taxes
555 735 €
↓ 33.6% vs Q2 2026
Employees
112
±0 vs Q2 2026
Q3 2026 · data from the Tax and Customs Board (EMTA)
Position in the industry
- Turnover · Q3 2026 7.8 mn €above 90% of companiesindustry median 234 187 € · companies in the industry: 12
- Labour taxes per employee 4 962 €above 63% of companiesindustry median 4 573 € · companies in the industry: 12
- Revenue · 2025 32.7 mn €above 98% of companiesindustry median 48 003 € · companies in the industry: 19
- Net profit margin · 2025 4.8 %above 38% of companiesindustry median 9.8 % · companies in the industry: 15
Taxes and turnover
- Company
- Industry median
Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.
- Company
- Industry median
Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.
| Quarter | Turnover, € | State taxes, € | Labour taxes, € | Employees |
|---|---|---|---|---|
| Q3 2026 | 7 770 168 | 517 739 | 555 735 | 112 |
| Q2 2026 | 8 743 761 | 780 491 | 837 475 | 112 |
| Q1 2026 | 10 743 068 | 486 096 | 517 015 | 114 |
| Q4 2025 | 11 373 621 | 514 235 | 540 210 | 116 |
| Q3 2025 | 9 083 319 | 573 889 | 606 167 | 114 |
| Q2 2025 | 10 335 673 | 803 023 | 854 016 | 117 |
| Q1 2025 | 6 824 642 | 499 385 | 525 101 | 116 |
| Q4 2024 | 6 738 212 | 463 699 | 489 808 | 108 |
| Q3 2024 | 7 568 627 | 446 706 | 471 134 | 106 |
| Q2 2024 | 8 196 598 | 574 248 | 607 763 | 104 |
| Q1 2024 | 7 346 327 | 418 259 | 438 521 | 104 |
| Q4 2023 | 8 124 461 | 446 448 | 469 144 | 104 |
| Q3 2023 | 5 652 436 | 414 969 | 434 892 | 104 |
| Q2 2023 | 8 184 641 | 532 092 | 561 776 | 102 |
| Q1 2023 | 5 704 328 | 387 602 | 406 252 | 101 |
| Q4 2022 | 6 096 542 | 363 461 | 380 871 | 99 |
| Q3 2022 | 4 815 158 | 352 661 | 373 410 | 100 |
| Q2 2022 | 5 433 964 | 508 358 | 540 005 | 93 |
| Q1 2022 | 5 103 475 | 295 006 | 309 809 | 88 |
Labour taxes per employee per month
1 654 €
Turnover per employee in the quarter
69 377 €
Q3 2026 · calculated from EMTA data
Financials by year
- Company
- Industry median
Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.
- Company
- Industry median
Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.
- Company
- Industry median
Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.
- Company
- Industry median
Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.
| Year | Revenue, € | Net profit, € | Labour costs, € | Assets, € | Equity, € | Employees |
|---|---|---|---|---|---|---|
| 2025 | 32 713 000 | 1 570 000 | 5 831 000 | 16 887 000 | 9 828 000 | 117 |
| 2024 | 26 382 000 | 1 058 000 | 4 945 000 | 14 209 000 | 8 258 000 | 105 |
| 2023 | 24 013 000 | 906 000 | 4 493 000 | 15 402 000 | 7 200 000 | 105 |
| 2022 | 17 929 806 | 2 004 000 | 3 917 000 | 10 080 000 | 6 294 000 | 93 |
| 2021 | 10 147 000 | 838 000 | 3 096 000 | 9 552 000 | 4 290 000 | 77 |
| 2020 | 7 674 000 | 379 000 | 2 691 000 | 5 588 000 | 3 452 000 | 69 |
| 2019 | 6 952 000 | 617 000 | 2 318 000 | 4 618 000 | 3 073 000 | 64 |
| 2018 | — | — | — | — | — | 62 |
| 2017 | — | — | — | — | — | 61 |
| 2016 | — | — | — | — | — | 53 |
Figures from the company’s own (non-consolidated) balance sheet and income statement. A loss is shown with a minus sign.
Financial ratios for 2025
Net profit margin
4.8 %
Net profit / revenue
Return on equity (ROE)
16.0 %
Net profit / equity
Return on assets (ROA)
9.3 %
Net profit / assets
Equity ratio
58.2 %
Equity / assets
Debt ratio
41.8 %
Liabilities / assets
Current ratio
1.34
Current assets / current liabilities
Revenue per employee
279 598 €
Revenue / average full-time employees
Labour cost per employee per month
4 153 €
Labour costs / employees / 12 months (incl. employer taxes)
Annual reports
| Year | Period | Filed | Report | Documents |
|---|---|---|---|---|
| 2025 | 1 Jan 2025 – 31 Dec 2025 | 29 May 2026 | Company’s own · audited | e-Äriregister |
| 2024 | 1 Jan 2024 – 31 Dec 2024 | 12 Jun 2025 | Company’s own · audited | e-Äriregister |
| 2023 | 1 Jan 2023 – 31 Dec 2023 | 17 Sep 2024 | Company’s own · audited | e-Äriregister |
| 2022 | 1 Jan 2022 – 31 Dec 2022 | 21 Jun 2023 | Company’s own · audited | e-Äriregister |
| 2021 | 1 Jan 2021 – 31 Dec 2021 | 17 Jun 2022 | Company’s own · audited | e-Äriregister |
| 2020 | 1 Jan 2020 – 31 Dec 2020 | 18 May 2021 | Company’s own · audited | e-Äriregister |
| 2019 | 1 Jan 2019 – 31 Dec 2019 | 20 Apr 2020 | Company’s own · audited | e-Äriregister |
Board
- Katrin MadissooBoard member · since 27 Apr 2018
- Arne RandmaaBoard member · since 25 Oct 2023
- Ebe LaanesBoard member · since 25 Oct 2023
Right of representation
Any member of the management board may represent the private limited company in all transactions.
Owners
- ACINO INTERNATIONAL AGLegal person · 3 000 €
Beneficial owners
- H.H. Sheikh Tahnoon Bin Zayed Al NahyanMember of a senior management body (management or supervisory board) · ARE · since 17 Jun 2022
Founders and other persons
- aktsiaselts Takeda PharmaFounder · 2 500 € · 30 Jun 2016
Related companies
Activities (EMTAK)
- 21101Manufacture of basic pharmaceutical products Main
Rulings
All rulings (PDF)| Number, date | Title | Deadline | State | Document |
|---|---|---|---|---|
| Ä 50032735 / 24 28 May 2026 |
Amendment entry | In force 28 May 2026 |
||
| Ä 50032735 / 23 12 Nov 2025 |
Amendment entry | In force 12 Nov 2025 |
||
| Ä 50032735 / 22 5 Jun 2025 |
Amendment entry | In force 5 Jun 2025 |
||
| Ä 50032735 / M11 4 Jun 2025 |
Ruling to eliminate deficiencies | 18 Jun 2025 | Deficiencies eliminated 5 Jun 2025 |
|
| Ä 50032735 / 21 18 Dec 2024 |
Amendment entry | In force 18 Dec 2024 |
||
| Ä 50032735 / 20 29 Nov 2024 |
Entry refused: deficiencies not eliminated | In force 17 Dec 2024 |
||
| Ä 50032735 / M10 31 Oct 2024 |
Ruling to eliminate deficiencies | 15 Nov 2024 | In force 16 Nov 2024 |
|
| Ä 50032735 / M9 17 Aug 2024 |
Warning of a fine: annual report not filed | 23 Sep 2024 | Deficiencies eliminated 18 Sep 2024 |
|
| Ä 50032735 / 19 25 Jul 2024 |
Entry refused: deficiencies not eliminated | In force 12 Aug 2024 |
||
| Ä 50032735 / M8 14 Jun 2024 |
Ruling to eliminate deficiencies | 4 Jul 2024 | In force 1 Jul 2024 |
|
| Ä 50032735 / 18 3 May 2024 |
Amendment entry | In force 3 May 2024 |
||
| Ä 50032735 / 17 3 May 2024 |
Amendment entry | In force 3 May 2024 |
||
| Ä 50032735 / 16 15 Dec 2023 |
Amendment entry | In force 15 Dec 2023 |
||
| Ä 50032735 / 15 25 Oct 2023 |
Amendment entry | In force 25 Oct 2023 |
||
| Ä 50032735 / M7 17 Oct 2023 |
Procedural ruling | 27 Oct 2023 | Deficiencies eliminated 19 Oct 2023 |
|
| Ä 50032735 / 14 21 Jul 2023 |
Amendment entry | In force 21 Jul 2023 |
||
| Ä 50032735 / M6 14 Jul 2023 |
Ruling to eliminate deficiencies | 13 Aug 2023 | Deficiencies eliminated 21 Jul 2023 |
|
| Ä 50032735 / 13 26 Apr 2023 |
Amendment entry | In force 26 Apr 2023 |
||
| Ä 50032735 / 12 3 Mar 2023 |
Amendment entry | In force 3 Mar 2023 |
||
| Ä 50032735 / 11 3 Mar 2023 |
Entry refused: deficiencies not eliminated | In force 22 Mar 2023 |
||
| Ä 50032735 / M5 9 Feb 2023 |
Ruling to eliminate deficiencies | 2 Mar 2023 | In force 28 Feb 2023 |
|
| Ä 50032735 / 10 26 Nov 2018 |
Amendment entry | In force 26 Nov 2018 |
||
| Ä 50032735 / M4 22 Nov 2018 |
Ruling to eliminate deficiencies | 22 Dec 2018 | Deficiencies eliminated 26 Nov 2018 |
|
| Ä 50032735 / M3 22 Nov 2018 |
Procedural ruling | 2 Dec 2018 | Deficiencies eliminated 22 Nov 2018 |
|
| Ä 50032735 / 9 27 Apr 2018 |
Amendment entry | In force 27 Apr 2018 |
||
| Ä 50032735 / 8 19 Jan 2018 |
Amendment entry | In force 19 Jan 2018 |
||
| Ä 50032735 / 7 12 Dec 2017 |
Amendment entry | In force 12 Dec 2017 |
||
| Ä 50032735 / 6 27 Sep 2017 |
Amendment entry | In force 27 Sep 2017 |
||
| Ä 50032735 / 5 7 Nov 2016 |
Amendment entry | In force 7 Nov 2016 |
||
| Ä 50032735 / 4 27 Oct 2016 |
Amendment entry | In force 27 Oct 2016 |
||
| Ä 50032735 / M2 24 Oct 2016 |
Ruling to eliminate deficiencies | 18 Nov 2016 | Deficiencies eliminated 26 Oct 2016 |
|
| Ä 50032735 / 3 1 Sep 2016 |
Amendment entry | In force 1 Sep 2016 |
||
| Ä 50032735 / M1 16 Aug 2016 |
Ruling to eliminate deficiencies | 15 Sep 2016 | Deficiencies eliminated 1 Sep 2016 |
|
| Ä 50032735 / 2 2 Jul 2016 |
Amendment entry | In force 2 Jul 2016 |
||
| Ä 50032735 30 Jun 2016 |
First entry | In force 30 Jun 2016 |
Sources: e-Äriregister and EMTA. Data updated 1 Nov 2026. Open at the source ↗ · Report an error in the data